GSK's former head of vaccines R&D – Dr Emmanuel ... a vaccine against respiratory syncytial virus (RSV) infections. The London-based company was founded by venture capital firm Medicxi in ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...

A Goodwin Procter team has advised on British pharmaceutical giant GSK’s $1.15 billion acquisition of a US biopharmaceutical ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

The Brentford, England-based pharmaceutical and biotechnology firm said it will pay USD1.00 billion upfront for IDRx, a developer of precision therapeutics for the treatment of gastrointestinal ...

London: GSK plc has announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

(RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company, for up to $1.15 billion ...

London stocks fell in early trade on Monday as bond yields rose again, but oil majors gained in tandem with oil prices.

London open The FTSE 100 is expected to open 17 points lower on Monday, having closed down 0.86% on Friday at 8,248.49.

(Alliance News) - GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemotherapy, to include all adult patients with primary advanced or ...